GLPwatch
Papers (12034)
Page 115 of 201, ranked by citation count.
- The Influence of Varying Cost Formats on Preferences.
- Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.
- Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.
- Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives.
- Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor.
- Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
- Severe, prolonged thrombocytopenia in a patient sensitive to exenatide.
- Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.
- Tirzepatide for type 2 diabetes.
- Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.
- [Exendin-4 promotes autophagy to relieve lipid deposition in a NAFLD cell model by activating AKT/mTOR signaling pathway].
- What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery?
- A LEAN treatment for non-alcoholic steatohepatitis.
- Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
- GLP-1 receptor agonists for the treatment of alcohol use disorder.
- The Hypoglycemic and Hypocholesterolemic Activity of <i>Dioscorea deltoidea</i>, <i>Tribulus terrestris</i> and <i>Panax japonicus</i> Cell Culture Biomass in Rats with High-Fat Diet-Induced Obesity.
- Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.
- Incretin effect of glucagon-like peptide 1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β-cell.
- Current and emerging pharmacotherapies for obesity in Australia.
- Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.
- Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.
- Novel ABCA1 peptide agonists with antidiabetic action.
- Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Synthesis and in vivo behaviour of an exendin-4-based MRI probe capable of β-cell-dependent contrast enhancement in the pancreas.
- The Impact of Liraglutide, a GLP-1 Receptor Agonist, on High Glucose-Induced Inflammation, Apoptosis, Oxidative Stress, and NLRP3 Signaling.
- Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats.
- Liraglutide intervention improves high-glucose-induced reactive gliosis of Müller cells and ECM dysregulation.
- Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis.
- Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
- Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.
- Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.
- Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys.
- Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
- The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
- Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo.
- Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.
- Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.
- Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
- Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience.
- Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.
- GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.
- Exendin-4 protects murine MIN6 pancreatic β-cells from interleukin-1β-induced apoptosis via the NF-κB pathway.
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
- Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
- Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.
- Effects of 6-month treatment with the GLP-1 receptor agonist liraglutide on 24-hour energy metabolism and body composition in adults with obesity.
- Effects of glucagon-like peptide-1 receptor agonists on spermatogenesis-related gene expression in mouse testis and testis-derived cell lines.
- Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue.
- Semaglutide ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice.
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
- Exenatide promotes cardiac lncRNAs HOX transcript antisense RNA (HOTAIR) in Wistar rats with liver cirrhosis; a novel role of GLP-1 receptor agonists in cirrhotic cardiomyopathy.
- Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial.
- Treatment of type 2 diabetes in children: what are the specific considerations?
- Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy.
- Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.
- Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
- Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving <i>in-situ</i> stability.
- Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial.